805250-31-1

Basic information

• Product Name: [1,1-Biphenyl]-3-carboxaldehyde,4-hydroxy-2,6-dimethyl-(9CI)
• Synonyms: [1,1-Biphenyl]-3-carboxaldehyde,4-hydroxy-2,6-dimethyl-(9CI);4'-hydroxy-2',6'-diMethylbiphenyl-3-carbaldehyde;[1,1'-Biphenyl]-3-carboxaldehyde,4'-hydroxy-2',6'-diMethyl-;4'-Hydroxy-2',6'-dimethyl-[1,1'-biphenyl]-3-carboxaldehyde;4'-Hydroxy-2',6'-dimethylbiphenyl-3-carboxaldehyde;[1,1-Biphenyl]-3-carboxaldehyde,4-hydroxy-2,6-dimethyl-(9CI)-4;4-Hydroxy-2,6-dimethyl-[1,1-biphenyl]-3-carbaldehyde
• CAS NO: 805250-31-1
• Molecular Formula: C₁₅H₁₄O₂
• Molecular Weight: 226.27046
• Product Categories: METHYL
• Mol File: 805250-31-1.mol
• Article Data: 18

Chemical Properties

• Boiling Point: 365.9±30.0 °C(Predicted)
• Appearance: /
• Density: 1.146±0.06 g/cm3 (20 ºC 760 Torr)
• PKA: 9.93±0.36(Predicted)
• CAS DataBase Reference: [1,1-Biphenyl]-3-carboxaldehyde,4-hydroxy-2,6-dimethyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: [1,1-Biphenyl]-3-carboxaldehyde,4-hydroxy-2,6-dimethyl-(9CI)(805250-31-1)
• EPA Substance Registry System: [1,1-Biphenyl]-3-carboxaldehyde,4-hydroxy-2,6-dimethyl-(9CI)(805250-31-1)

Safety Data

• Hazardous Substances Data: 805250-31-1(Hazardous Substances Data)

Usage

General Description

"[1,1-Biphenyl]-3-carboxaldehyde,4-hydroxy-2,6-dimethyl-(9CI)" is a chemical compound. These types of compounds are typically used in the field of organic chemistry, possibly for pharmaceutical development, agrochemical production, or polymer production. Its structure, comprised of a biphenyl group and a carboxaldehyde group, suggests that it may have aromatic properties. The "4-hydroxy-2,6-dimethyl" designation further describes specific functional groups present in the molecule. Its full characteristics, such as reactivity, toxicity, and other chemical properties would be determined by these functional groups and their arrangement. Like any chemical, it should be handled using appropriate safety precautions, typically outlined in an associated safety data sheet.

Upstream product

• 7463-51-6 4-bromo-3,5-dimethylphenol 
• 87199-16-4 3-Formylphenylboronic acid 

Downstream Products

• 1000413-84-2 2',6'-dimethyl-4'-(3-(methylsulfonyl)propoxy)-[1,1'-biphenyl]-3-carbaldehyde 
• 805250-48-0 4'-(benzyloxy)-2',6'-dimethylbiphenyl-3-carbaldehyde 

Relevant articles and documents

Nitric oxide donor-based FFA1 agonists: Design, synthesis and biological evaluation as potential anti-diabetic and anti-thrombotic agents

The cardiovascular complications were highly prevalent in type 2 diabetes mellitus (T2DM), even at the early stage of T2DM or the state of intensive glycemic control. Thus, there is an urgent need for the intervention of cardiovascular complications in T2DM. Herein, the new hybrids of FFA1 agonist and NO donor were design to obtain dual effects of anti-hyperglycemic and anti-thrombosis. As expected, the induced-fit docking study suggested that it is feasible for our design strategy to hybrid NO donor with compound 1. These hybrids exhibited moderate FFA1 agonistic activities and anti-platelet aggregation activities, and their anti-platelet effects mediated by NO were also confirmed in the presence of NO scavenger. Moreover, compound 3 revealed significantly hypoglycemic effect and even stronger than that of TAK-875 during an oral glucose tolerance test in mice. Potent and multifunctional hybrid, such as compound 3, is expected as a potential candidate with additional cardiovascular benefits for the treatment of T2DM.

Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold

Based on an old phenoxyacetic acid scaffold, CPU014 (compound 14) has been identified as a superior agonist by comprehensive exploration of structure-activity relationship. In vitro toxicity study suggested that CPU014 has lower risk of hepatotoxicity than TAK-875. During acute toxicity study (5–500 mg/kg), a favorable therapeutic window of CPU014 was observed by evaluation of plasma profiles and liver slices. Moreover, CPU014 promotes insulin secretion in a glucose-dependent manner, while no GLP-1 secretion has been enhanced. Other than good pharmacokinetic properties, CPU014 significantly improved glucose tolerance both in normal and diabetic models without the risk of hypoglycemia. These subversive findings provided a safer candidate CPU014, which is currently in preclinical study to assess its potential for the treatment of diabetes.

Design, synthesis, and evaluation of a series of novel phenylpropanoic acid derivatives agonists for the FFA1

Free fatty acid 1 (FFA1/GPR40) has attracted extensive attention as a novel target for the treatment of type 2 diabetes for its role in the enhancement of insulin secretion with glucose dependency. Aiming to develop novel potent FFA1 agonists, a new series of phenylpropionic acid derivatives were designed and synthesized on the basis of the modification of chemical cement of TAK-875, AMG-837, and LY2881835. Among them, most promising compounds 7, 14, and 15 were obtained with EC50 values of 82, 79, and 88?nM, exhibiting a powerful agonistic activity compared to TAK-875 (95.1?nM). During Oral glucose tolerance test in normal mice, compound 7, 14, and 15 had significant glucose-lowering effect at the dose of 50?mg/kg. Furthermore, compound 15 (50?mg/kg) also significantly improved in glucose tolerance in type 2 diabetic mice. Herein, we reported the discovery and optimization of a series of potent FFA1 agonists. The discovery supported further exploration surrounding this scaffold.